Infection Immunology Research Group, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Front Immunol. 2024 Oct 29;15:1461455. doi: 10.3389/fimmu.2024.1461455. eCollection 2024.
Myeloid-derived suppressor cells (MDSC) are considered an aberrant population of immature myeloid cells that have attracted considerable attention in recent years due to their potent immunosuppressive activity. These cells are typically absent or present in very low numbers in healthy individuals but become abundant under pathological conditions such as chronic infection, chronic inflammation and cancer. The immunosuppressive activity of MDSC helps to control excessive immune responses that might otherwise lead to tissue damage. This same immunosuppressive activity can be detrimental, particularly in cancer and chronic infection. In the cancer setting, tumors can secrete factors that promote the expansion and recruitment of MDSC, thereby creating a local environment that favors tumor progression by inhibiting the effective immune responses against cancer cells. This has made MDSC a target of interest in cancer therapy, with researchers exploring strategies to inhibit their function or reduce their numbers to improve the efficacy of cancer immunotherapies. In the context of chronic infections, MDSC can lead to persistent infections by suppressing protective immune responses thereby preventing the clearance of pathogens. Therefore, targeting MDSC may provide a novel approach to improve pathogen clearance during chronic infections. Ongoing research on MDSC aims to elucidate the exact processes behind their expansion, recruitment, activation and suppressive mechanisms. In this context, it is becoming increasingly clear that the metabolism of MDSC is closely linked to their immunosuppressive function. For example, MDSC exhibit high rates of glycolysis, which not only provides energy but also generates metabolites that facilitate their immunosuppressive activity. In addition, fatty acid metabolic pathways, such as fatty acid oxidation (FAO), have been implicated in the regulation of MDSC suppressive activity. Furthermore, amino acid metabolism, particularly arginine metabolism mediated by enzymes such as arginase-1, plays a critical role in MDSC-mediated immunosuppression. In this review, we discuss the metabolic signature of MDSC and highlight the therapeutic implications of targeting MDSC metabolism as a novel approach to modulate their immunosuppressive functions.
髓源性抑制细胞(MDSC)被认为是一种异常的未成熟髓系细胞群体,由于其强大的免疫抑制活性,近年来引起了相当大的关注。这些细胞在健康个体中通常不存在或存在数量非常少,但在慢性感染、慢性炎症和癌症等病理条件下变得丰富。MDSC 的免疫抑制活性有助于控制可能导致组织损伤的过度免疫反应。这种相同的免疫抑制活性可能是有害的,特别是在癌症和慢性感染中。在癌症环境中,肿瘤可以分泌促进 MDSC 扩增和募集的因子,从而创造有利于肿瘤进展的局部环境,抑制针对癌细胞的有效免疫反应。这使得 MDSC 成为癌症治疗的一个关注目标,研究人员正在探索抑制其功能或减少其数量的策略,以提高癌症免疫疗法的疗效。在慢性感染的情况下,MDSC 通过抑制保护性免疫反应导致持续感染,从而防止病原体清除。因此,靶向 MDSC 可能为改善慢性感染期间病原体清除提供一种新方法。目前对 MDSC 的研究旨在阐明其扩增、募集、激活和抑制机制的确切过程。在这种情况下,越来越清楚的是,MDSC 的代谢与它们的免疫抑制功能密切相关。例如,MDSC 表现出高糖酵解率,这不仅提供能量,而且产生促进其免疫抑制活性的代谢物。此外,脂肪酸代谢途径,如脂肪酸氧化(FAO),已被牵连调节 MDSC 抑制活性。此外,氨基酸代谢,特别是由精氨酸酶-1 等酶介导的精氨酸代谢,在 MDSC 介导的免疫抑制中发挥关键作用。在这篇综述中,我们讨论了 MDSC 的代谢特征,并强调了靶向 MDSC 代谢作为调节其免疫抑制功能的新方法的治疗意义。